Cullinan Therapeutics, Inc.
CGEM· Nasdaq
Released Aug 7, 2025, before the open
10-Q filed Aug 7, 2025, 38 days after period end · 0000950170-25-104551
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | — | — | — | $0.00 |
| Net Income | -$70.06M | -$42.03M | -$32.21M | $174.90M |
| EPS Diluted |
Cullinan Therapeutics, Inc. · CIK 1789972 · Engraved from SEC EDGAR
| — |
| -$0.75 |
| -$0.82 |
| $3.77 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.